Drugs of Choice for Fungal Peritonitis
For fungal peritonitis, an echinocandin (caspofungin, micafungin, or anidulafungin) is the drug of choice for initial therapy, with fluconazole as an acceptable alternative in non-critically ill patients with susceptible Candida species. 1
Initial Antifungal Selection
The treatment approach depends on the clinical context and patient severity:
For Intra-Abdominal Candidiasis (Including Secondary Peritonitis)
Echinocandins are first-line:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
This recommendation mirrors the treatment for candidemia and empiric therapy in critically ill ICU patients 1. The choice of antifungal therapy for intra-abdominal candidiasis is explicitly stated to be the same as for candidemia 1.
Fluconazole as alternative:
- 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily
- Appropriate for non-critically ill patients who are unlikely to have fluconazole-resistant species 1
- Should NOT be used empirically in critically ill patients or those with prior azole exposure
For Peritoneal Dialysis-Associated Fungal Peritonitis
The evidence shows fluconazole has been the most commonly used agent (80% of cases) 2, though this reflects historical practice rather than optimal therapy. More recent data supports:
- Amphotericin B formulations (particularly liposomal amphotericin B 3-5 mg/kg daily) for severe cases 3
- Fluconazole remains appropriate for susceptible Candida species after identification 4, 5
- Combination therapy with amphotericin B + flucytosine has shown promise in some series 6
Critical Management Principles
Source Control is Mandatory
Surgical intervention and drainage are strongly recommended alongside antifungal therapy 1. For peritoneal dialysis patients, catheter removal is usually required (performed in 90% of cases) 2, though delayed removal after effluent clearing has been attempted in select cases 6.
Empiric Therapy Indications
Empiric antifungal therapy should be considered in:
- Critically ill patients with septic shock and intra-abdominal infection 7
- Patients with post-operative infections 7
- Those with recent bacterial peritonitis (especially if polymicrobial or enterococcal) and exposure to multiple antibiotics 2
- Patients with anastomotic leaks or necrotizing pancreatitis 1
Species-Specific Considerations
Candida parapsilosis is now the most common pathogen in peritoneal dialysis-associated fungal peritonitis (replacing C. albicans) 8, 2. Testing for antifungal susceptibility is strongly recommended for all clinically relevant isolates 1.
For non-albicans Candida species:
- C. glabrata and emerging NAC species may require treatment escalation 8
- Echinocandin susceptibility testing should be considered, especially with prior echinocandin exposure 1
Treatment Duration
Duration should be determined by:
- Adequacy of source control 1
- Clinical response 1
- For peritoneal dialysis patients: typically 3-4 weeks total when catheter is removed 6
Common Pitfalls
⚠️ Do NOT use fluconazole empirically in critically ill patients - echinocandins have superior outcomes in this population
⚠️ Do NOT delay source control - antifungals alone are insufficient; surgical drainage/debridement and catheter removal are essential
⚠️ Watch for hepatotoxicity with amphotericin B + flucytosine combinations - close monitoring is paramount 6
⚠️ Recent bacterial peritonitis is a major risk factor - particularly if treated with multiple broad-spectrum antibiotics or involving polymicrobial/enterococcal infections 2
Step-Down Therapy
Once susceptibility results are available and the patient is clinically stable: